Leerink Partnrs Has Weak Outlook for Zoetis FY2025 Earnings

Zoetis Inc. (NYSE:ZTS) – Leerink Partnrs dropped their FY2025 earnings estimates for shares of Zoetis in a report released on Thursday, February 13th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings per share of $6.09 for the year, down from their prior estimate of $6.19. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Leerink Partnrs also issued estimates for Zoetis’ Q4 2025 earnings at $1.39 EPS, Q4 2025 earnings at $1.39 EPS, FY2025 earnings at $6.09 EPS, FY2026 earnings at $6.82 EPS, FY2027 earnings at $7.46 EPS, FY2027 earnings at $7.46 EPS, FY2028 earnings at $8.10 EPS and FY2028 earnings at $8.10 EPS.

Several other research analysts have also weighed in on ZTS. Morgan Stanley dropped their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Barclays upped their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Piper Sandler reduced their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Finally, UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $214.90.

Zoetis Price Performance

Shares of ZTS opened at $156.43 on Monday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The company has a market capitalization of $70.58 billion, a price-to-earnings ratio of 29.40, a P/E/G ratio of 2.77 and a beta of 0.90. The business’s 50-day moving average is $168.10 and its 200-day moving average is $178.61. Zoetis has a fifty-two week low of $144.80 and a fifty-two week high of $200.53.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.28%. Zoetis’s dividend payout ratio is 37.59%.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Pacific Point Advisors LLC acquired a new position in Zoetis in the 4th quarter valued at approximately $878,000. Vega Investment Solutions bought a new position in Zoetis in the fourth quarter worth $720,000. Breed s Hill Capital LLC boosted its stake in Zoetis by 16.1% during the fourth quarter. Breed s Hill Capital LLC now owns 3,606 shares of the company’s stock worth $588,000 after buying an additional 499 shares in the last quarter. Vise Technologies Inc. increased its holdings in Zoetis by 64.1% in the 4th quarter. Vise Technologies Inc. now owns 5,602 shares of the company’s stock valued at $913,000 after buying an additional 2,189 shares during the period. Finally, Navalign LLC raised its stake in shares of Zoetis by 3.9% in the 4th quarter. Navalign LLC now owns 5,638 shares of the company’s stock valued at $919,000 after buying an additional 212 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.